Adaptive Biotechnologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Adaptive Biotechnologies şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.02%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 1HM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 1HM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Adaptive Biotechnologies Piyasaya Karşı Temettü Getirisi

1HM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (1HM)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.9%
Sektör Ortalaması (Life Sciences)	0.7%
Analist tahmini (1HM) (3 yıla kadar)	0%

Önemli Temettü: 1HM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 1HM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 1HM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 1HM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Adaptive Biotechnologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Insufficient new directors

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Insufficient new directors

Adaptive Biotechnologies Corporation Announces Executive Changes

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insufficient new directors

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023

Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023

Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Chief Commercial Officer of MRD recently sold €190k worth of stock

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q2, 2022 Results on Aug 03, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

Adaptive Biotechnologies Corporation Includes in Several Abstracts Investigating the Impact of Mrd in Blood Cancers At the American Society of Clinical Oncology

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2022

Adaptive Biotechnologies Corporation to Report Q1, 2022 Results on May 04, 2022

President recently sold €51k worth of stock

Adaptive Biotechnologies Corporation Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Provides Earnings Guidance for Full Year 2021

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)

Adaptive Biotechnologies Corporation Announces New Study Published in Nature Provides Further Evidence COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)

Adaptive Biotechnologies Corporation Provides Financial Guidance for 2021

Insider recently sold €128k worth of stock

Adaptive Biotechnologies Corporation Announces Board Changes

Independent Director has left the company

Independent Director has left the company

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

New 90-day low: €36.40

Adaptive Biotechnologies Corporation and Genentech, Inc. Collaborate the Development of Cellular Therapy Drugs for Treating Cancer by Targeting Immune Cells to Specific Shared and Personalized Cancer-Related Antigen Targets

Full year 2020 earnings released: US$1.11 loss per share (vs US$1.01 loss in FY 2019)

Revenue beats expectations

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

Adaptive Biotechnologies Corporation to Report Q4, 2020 Results on Feb 24, 2021

Adaptive Biotechnologies Corporation Announces Executive Changes

Adaptive Biotechnologies Corporation Collaborates with AstraZeneca PLC in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers At the 62nd ASH Annual Meeting

Adaptive Biotechnologies Corporation Announces Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections

Adaptive Biotechnologies Corporation Provides Financial Guidance for the Full Year 2020

Adaptive Biotechnologies Corporation Announces Resignation of Andris Zoltners as Director

Adaptive Biotechnologies Corporation to Report Q3, 2020 Results on Nov 10, 2020

Adaptive Biotechnologies Corporation Does Not Provide 2020 Financial Guidance

Adaptive Biotechnologies Corporation has completed a Follow-on Equity Offering in the amount of $320 million.

Adaptive Biotechnologies Corporation to Report Q2, 2020 Results on Aug 10, 2020

Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) dropped from Russell Midcap Value Index

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin